CaSRevolution, a research company, studies neurodegeneration therapies; it discovered an Alzheimer’s disease progression mechanism and identified a potential therapeutic approach.
CaSRevolution researches therapies for neurodegenerative diseases, drawing on its discovery of a mechanism that explains Alzheimer's disease progression and its identification of a potential therapeutic approach; its research targets the CaSR transmembrane receptor with molecules designed to cross the blood-brain barrier. Its development plan draws on literature analyses of Alzheimer's disease, the CaSR transmembrane receptor, and molecules known to modulate the CaSR receptor response.
The company aims to develop these molecules with support from selected research institutes. No effective treatments for the pathology are on the market, and the company aims for a highly effective therapy rather than a palliative treatment.
